Patents by Inventor Richard J. Deckelbaum
Richard J. Deckelbaum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240050391Abstract: In various aspects and embodiments of the disclosure, the invention provides pharmaceutical compositions and methods for protecting against brain injury associated with Hypoxic-Ischemic Encephalopathy (HIE). The compositions and methods employ omega-3 fatty acid (n-3 FA) diglyceride (DG) and/or triglyceride (TG) emulsions, which may be used alone or in combination with therapeutic Hypothermia (HT).Type: ApplicationFiled: December 7, 2021Publication date: February 15, 2024Inventors: Richard J. DECKELBAUM, Hylde ZIRPOLI, Soren Weis DAHL, Vadim S. TEN
-
Publication number: 20230241124Abstract: Isotonic lipid emulsion for use in the treatment of a number of diseases such as an acute heart ischemia, a brain ischemia or another organ damage which occurred on a day, where the treatment is applied by intravenous bolus injection which is repeated at time intervals during at least that day at which the disease occurred, the isotonic lipid emulsion comprising a 78 to 95% by weight of medium chain triglycerides and 5 to 22% by weight of a substance, said substance being either a fish oil, wherein the fish oil has an eicosapentaenoic acid content of from 20 to 50% by weight; or an eicosapentaenoic acid, or a docosapentaenoic acid, or a docosahexaenoic acid, or a combination of eicosapentaenoic acid, and/or docosapentaenoic acid, and/or docosahexaenoic acid.Type: ApplicationFiled: July 13, 2021Publication date: August 3, 2023Inventors: Yvon CARPENTIER, Richard J. DECKELBAUM, Chuchun CHANG
-
Publication number: 20230190693Abstract: The present invention provides compositions and methods involving stable omega-3 diglyceride oil-in-water emulsions for acute therapy to treat and/or prevent tissue or organ injury. The compositions provide protection from cellular death, and find use in patients in need of neuroprotection. For example, the compositions find use in treating ischemia reperfusion injuries, such as ischemic stroke. The compositions further find use for treatment of traumatic injuries, such as traumatic brain injury or spinal cord injury, among others. The compositions have a large time window by which they are effective after onset of traumatic or ischemic injury (e.g., after onset of stroke), and may be administered in conjunction with other therapies.Type: ApplicationFiled: April 15, 2021Publication date: June 22, 2023Inventors: Richard J. Deckelbaum, Chuchun Liz Chang, Hylde Zirpoli
-
Patent number: 11076593Abstract: It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2.Type: GrantFiled: August 27, 2018Date of Patent: August 3, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard J. Deckelbaum, Ravichandran Ramasamy
-
Publication number: 20190000072Abstract: It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2.Type: ApplicationFiled: August 27, 2018Publication date: January 3, 2019Inventors: Richard J. Deckelbaum, Ravichandran Ramasamy
-
Patent number: 10070643Abstract: It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2.Type: GrantFiled: March 28, 2014Date of Patent: September 11, 2018Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard J. Deckelbaum, Ravichandran Ramasamy
-
Publication number: 20160050909Abstract: It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2.Type: ApplicationFiled: March 28, 2014Publication date: February 25, 2016Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard J. Deckelbaum, Ravichandran Ramasamy
-
Publication number: 20150272921Abstract: The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 trigylceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.Type: ApplicationFiled: June 12, 2015Publication date: October 1, 2015Applicant: The Trustees of Columbia University in the City of New YorkInventors: Richard J. Deckelbaum, Susan J. Vannucci
-
Patent number: 9144562Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: GrantFiled: December 10, 2013Date of Patent: September 29, 2015Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard J. Deckelbaum, Yvon Carpentier
-
Patent number: 9084801Abstract: The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 trigylceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.Type: GrantFiled: December 23, 2011Date of Patent: July 21, 2015Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard J. Deckelbaum, Susan J. Vannucci
-
Publication number: 20140287004Abstract: The present invention provides methods of limiting cell death or damage or reperfusion damage resulting from hypoxic-ischemia, comprising administering an omega-3 triglyceride emulsion after a hypoxic-ischemia insult. The omega-3 triglyceride emulsion preferably comprises from about 7% to 35% omega-3 oil by weight in grams per 100 ml of emulsion; the omega-3 oil comprises about 20% to 100% triglyceride by weight per total weight of the omega-3 oil and about 20% wt.-% to 100% of the acyl-groups of the omega-3 triglycerides consist of DHA; the omega-3 oil comprises less than 10% omega-6 fatty acids; and the mean diameter of lipid droplets in the emulsion is less than about 5 microns.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventor: Richard J. Deckelbaum
-
Publication number: 20140099345Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Richard J. Deckelbaum, Yvon Carpentier
-
Patent number: 8633253Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: GrantFiled: July 29, 2013Date of Patent: January 21, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard J. Deckelbaum, Yvon Carpentier
-
Publication number: 20130315968Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: ApplicationFiled: July 29, 2013Publication date: November 28, 2013Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard J. Deckelbaum, Yvon Carpentier
-
Patent number: 8536232Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicosapentaenoic acid (EPA) groups and/or docosahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: GrantFiled: March 4, 2013Date of Patent: September 17, 2013Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard J. Deckelbaum, Yvon Carpentier
-
Publication number: 20130178528Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicant: The Trustees of Columbia University in The City of New YorkInventors: Richard J. DECKELBAUM, Yvon CARPENTIER
-
Patent number: 8410181Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt. -% of the acyl-groups of said diglycerides, are eicosapentaenoic acid (EPA) groups and/or docosahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: GrantFiled: September 19, 2007Date of Patent: April 2, 2013Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard J. Deckelbaum, Yvon Carpentier
-
Publication number: 20120095095Abstract: The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 trigylceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.Type: ApplicationFiled: December 23, 2011Publication date: April 19, 2012Applicant: The Trustees of Columbia University in the City of New YorkInventors: Richard J. DECKELBAUM, Susan J. VANNUCCI
-
Publication number: 20100093856Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt. -% of the acyl-groups of said diglycerides, are eicosapentaenoic acid (EPA) groups and/or docosahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: ApplicationFiled: September 19, 2007Publication date: April 15, 2010Inventors: Richard J. Deckelbaum, Yvon Carpentier
-
Publication number: 20020155161Abstract: This invention provides compositions in the form of emulsions comprising pharmaceutical agents, triglycerides and emulsifiers. This invention also provides methods for delivering pharmaceutical agents to predetermined tissues comprising administering the instant compositions. This invention also provides methods of making the instant compositions.Type: ApplicationFiled: December 28, 2001Publication date: October 24, 2002Inventors: Richard J. Deckelbaum, Yvon A. Carpentier